Compare DNN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | WVE |
|---|---|---|
| Founded | 1954 | 2012 |
| Country | Canada | Singapore |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 1997 | 2015 |
| Metric | DNN | WVE |
|---|---|---|
| Price | $4.14 | $12.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $29.94 |
| AVG Volume (30 Days) | ★ 54.3M | 4.7M |
| Earning Date | 03-12-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,493,456.00 | ★ $109,230,000.00 |
| Revenue This Year | $197.29 | N/A |
| Revenue Next Year | $55.12 | $16.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.35 | ★ 103.75 |
| 52 Week Low | $1.08 | $5.28 |
| 52 Week High | $4.43 | $21.73 |
| Indicator | DNN | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 73.15 | 41.30 |
| Support Level | $3.66 | $12.55 |
| Resistance Level | $4.43 | $13.77 |
| Average True Range (ATR) | 0.22 | 0.81 |
| MACD | 0.05 | -0.26 |
| Stochastic Oscillator | 78.26 | 11.70 |
Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.